Table 4.
HF re-hospitalization (N/%) | Before PSM | After PSM | |||||||
---|---|---|---|---|---|---|---|---|---|
iDGX (Ref.) | cDGX | OR (95% CI) | P -value | iDGX (Ref.) | cDGX | OR (5% CI) | P -value | ||
Unadjusted | 1-year | 62 (18.1) | 102 (28.1) | 1.77 (1.23–2.52) | 0.002 | 59 (42.8) | 79 (57.2) | 1.54 (1.05–2.26) | 0.026 |
3-year | 108 (35.9) | 165 (52.4) | 1.97 (1.42–2.72) | <0.001 | 101 (44.1) | 128 (55.9) | 1.69 (1.20–2.38) | 0.003 | |
5-year | 138 (51.7) | 206 (70.3) | 2.21 (1.56–3.13) | <0.001 | 130 (43.9) | 166 (56.1) | 2.08 (1.44–3.02) | <0.001 | |
Model 1a | 1-year | 62 (18.1) | 102 (28.1) | 1.50 (1.03–2.18) | 0.036 | 59 (42.8) | 79 (57.2) | 1.39 (0.93–2.08) | 0.106 |
3-year | 108 (35.9) | 165 (52.4) | 1.75 (1.24–2.45) | 0.001 | 101 (44.1) | 128 (55.9) | 1.55 (1.08–2.22) | 0.018 | |
5-year | 138 (51.7) | 206 (70.3) | 2.01 (1.40–2.90) | <0.001 | 130 (43.9) | 166 (56.1) | 1.98 (1.34–2.94) | 0.001 | |
Model 2b | 1-year | 62 (18.1) | 102 (28.1) | 1.31 (0.87–1.97) | 0.191 | 59 (42.8) | 79 (57.2) | 1.25 (0.81–1.93) | 0.305 |
3-year | 108 (35.9) | 165 (52.4) | 1.52 (1.05–2.21) | 0.027 | 101 (44.1) | 128 (55.9) | 1.62 (1.08–2.42) | 0.020 | |
5-year | 138 (51.7) | 206 (70.3) | 1.67 (1.12–2.54) | 0.012 | 130 (43.9) | 166 (56.1) | 1.75 (1.14–2.68) | 0.011 | |
Model 3c | 1-year | 62 (18.1) | 102 (28.1) | 1.29 (0.85–1.94) | 0.230 | 59 (42.8) | 79 (57.2) | 1.22 (0.79–1.88) | 0.366 |
3-year | 108 (35.9) | 165 (52.4) | 1.51 (1.04–2.19) | 0.030 | 101 (44.1) | 128 (55.9) | 1.53 (1.03–2.29) | 0.037 | |
5-year | 138 (51.7) | 206 (70.3) | 1.68 (1.11–2.52) | 0.013 | 130 (43.9) | 166 (56.1) | 1.61 (1.05–2.50) | 0.031 |
Model 1: adjusting for baseline adjustment covariates, including age, gender, smoking, drinking, disease duration, NYHA, cardiac valve damage, surgical intervention, medical condition (HT, CHD, T2D, AF at enrolment, and stroke), blood biochemical index (WBC, HGB, PLT, FBG, ALT, AST, Cr, ASO, RF, ESR, BNP, TRIG, TC, LDL-C, HDL-C, serum sodium, and serum potassium), and echocardiography (LAD, LVD, RVD, RAD, and LVEF).
Model 2: It was the same as model 1 and also included new-onset AF and combined medication (antiplatelet drugs, warfarin, nitrates, RSIs, BBs, MRAs, CCBs, and statins).
Model 3: It was the same as model 2 and also included SDC.
The bold values mean P value < 0.05.